Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lutetium 177 rosopatamab tetraxetan - Telix Pharmaceuticals

Next Previous
Drug Profile

Lutetium 177 rosopatamab tetraxetan - Telix Pharmaceuticals

Alternative Names: 177-Lu-DOTA-Rosopatamab - Telix Pharmaceuticals; 177Lu-DOTA-rosopatamab; 177Lu-DOTA-rosopatamb; 177Lu-DOTA-TLX591; 177Lu-DOTA-TLX591-CHO; 177Lu-TLX-591; Lutetium 177 DOTA rosopatamab - Telix Pharmaceuticals; Lutetium 177 rosopatamab - Telix Pharmaceuticals; TLX 591; TLX591-Tx; TLX591t; TX591

Latest Information Update: 03 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Telix Pharmaceuticals
  • Class Antineoplastics; Immunoconjugates; Monoclonal antibodies; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Prostate cancer

Most Recent Events

  • 20 Feb 2026 Telix Pharmaceuticals terminates a phase-III clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in New Zealand and Australia (IV), to focus on the ongoing phase III ProstACT Global trial (NCT06520345), aimed at accelerating development and approval under an IND (NCT04876651)
  • 08 Dec 2025 Telix plans to submits clinical trial application (CTA) to the European Medicines Agency (EMA) for ProstACT Global phase III trial for the treatment of Prostate cancer
  • 22 Aug 2024 Phase-III clinical trials in Prostate cancer (Combination therapy, Hormone refractory, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT04876651)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top